WilliamELuginbuhlMD

Oncology • Exton, PA

Medical Director Abramson Cancer Center West Chester

Join to view full profile

Dr. Luginbuhl is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Luginbuhl's full profile

Already have an account?

Office
720 W Lincoln Hwy
Exton, PA 19341
Phone+1 800-789-7366

Fax+1 610-738-2570
Is this information wrong?

Summary

I am a board certified hematologist and medical oncologist, interested in several areas including lung cancer, gynecologic oncology, general hematology including hematologic malignancies. I am involved in clinical research and serve as the principle investigator at our institution.

Education & Training

University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 1990 - 1993
University of FloridaResidency, Internal Medicine, 1987 - 1990
University of Vermont College of MedicineClass of 1987

Certifications & Licensure

PA State Medical License 1990 - 2024
FL State Medical License 1988 - 1991
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
Active, not recruiting
Phase 3
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Completed
Phase 3
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
S0820, Adenoma and Second Primary Prevention Trial Start of enrollment: 2013 Aug 23
Active, not recruiting
Phase 3
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
Active, not recruiting
Phase 3
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2014 Jan 24
Active, not recruiting
Phase 2
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Start of enrollment: 2014 Jan 15
Active, not recruiting
Phase 3
S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer Start of enrollment: 2015 May 07
Active, not recruiting
Phase 2, Phase 3
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Start of enrollment: 2015 Jul 26
Recruiting
Phase 3
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Isolated Ovarian Metastasis from Pancreatic Cancer Mimicking Primary Ovarian Neoplasia: Role of Molecular Analysis in Determining Diagnosis
Catherine M. Tucker, Cheryl L. Godcharles, Wei Jiang, Charles J. Yeo, Norman G. Rosenblum, Ethan J. Halpern, William E. Luginbuhl, Anthony Prestipino> ;Journal of Pancreatic Cancer. 2021 Oct 14
22 citations
Phase II Trial of All-Trans Retinoic Acid in Metastatic Non-Small Cell Lung Cancer
Joseph Treat, David Friedland, William E. Luginbuhl, Lorraine Meehan, Genevieve Gorman, Wallace T. Miller, Joseph E. Bavaria, Larry R. Kaiser> ;Cancer Investigation. 1996 Jan 1
41 citations
The current status of toxicity protectants in cancer therapy
Lynn M. Schuchter, William E. Luginbuhl, Neal J. Meropol> ;Seminars in Oncology. 1992 Dec 1
7 citations
Leukocytosis Associated With All- Trans -Retinoic Acid Therapy in Metastatic Non-Small-Cell Lung Cancer
Marc J. Kahn, William E. Luginbuhl, Lesley Gaines, Jane Bratschi, Joseph E. Bavaria, Larry R. Kaiser, Joseph Treat> ;Journal of the National Cancer Institute. 1992 Nov 4
13 citations
Phenytoin-carbamazepine cross-sensitivity.
Stan Reents, William E. Luginbuhl, Steven M. Davis> ;DICP. 1989 Mar 1
Phase II trial of 5-fluorouracil and leucovorin in combination with interferon-alpha and interleukin-2 for advanced renal cell cancer.
Rathmell, W. K., Malkowicz, S. B., Holroyde, C., Luginbuhl, W., Vaughn, D. J.> ;Am J Clin Oncol. 2004 Apr
Join now to see all

Research History

Chester County Cancer Center Principle Investigator2004 - Present

Professional Memberships

American College of Physicians - ACP
Member
American Society of Clinical Oncology - ASCO
Member

Hospital Affiliations

Penn Medicine Chester County HospitalWest Chester, Pennsylvania
Penn Presbyterian Medical CenterPhiladelphia, Pennsylvania